Karo Bio AB Achieves First Milestone in Pfizer Inc. Collaboration

STOCKHOLM, 5 September 2013 – The collaboration between Karo Bio AB and Pfizer Inc. has successfully resulted in a significant achievement within the RORgamma project triggering the first milestone payment to Karo Bio. The purpose of the collaboration is to develop drugs for treatment of autoimmune diseases. “The teams from Karo Bio and Pfizer have enjoyed an excellent interaction and relationship which has helped meet this goal. This achievement clearly demonstrates the value Karo Bio brings to its partners in the area of nuclear receptor drug discovery”, says Karo Bio’s CEO Per Bengtsson.

Help employers find you! Check out all the jobs and post your resume.